As PDGFRA overexpression correlated with decreased survival of patients with IDH1-mutant AML, we reason that treatment with TKI dasatinib may present a novel therapeutic option for improved treatment for patients with IDH1 p.R132H mutant AML. Here, PDGFRA is linked to acute myeloid leukemia.